We studied the effect of an eight-week treatment with telmisartan (5 mg kg(-1)day(-1)) on cardiovascular complications that are associated with type 2 diabetes in a neonatal rat model. Type 2 diabetes was induced by the administration of 90 mg/kg streptozotocin (STZ), ip, in two-day-old rats. The development of diabetes was checked 12 weeks after STZ administration, and the animals were divided into different groups. Telmisartan treatment was given for eight weeks. At the end of the eight-week treatment, various biochemical and cardiac parameters were measured. Diabetic rats exhibited hyperglycemia, hyperinsulinemia, hyperlipidemia, increased blood pressure and heart rate, increased creatinine, cardiac enzyme and C-reactive protein (CRP) levels, a reduction in the rate of pressure development and decay, cardiac hypertrophy and oxidative stress. Chronic treatment with telmisartan significantly prevented STZ-induced hypertension and tachycardia and elevated fasting glucose and insulin levels. It significantly prevented the dyslipidemia and significantly reduced the elevated creatinine and CRP levels and the levels of other cardiac enzyme markers, like lactate dehydrogenase and creatinine kinase, in diabetic rats. There was an increase in rate of blood pressure development and decay with telmisartan treatment. Telmisartan also produced beneficial effects by preventing cardiac hypertrophy, which was evident from left ventricular collagen levels, the cardiac hypertrophy index and the left ventricular hypertrophy index in diabetic rats. Telmisartan successfully prevented oxidative stress, which was evidenced by a decrease in malondialdehyde and an increase in glutathione, catalase, superoxide dismutase levels. In conclusion, our data suggest that telmisartan prevented STZ-induced metabolic abnormalities and cardiovascular complications in type 2 diabetes.
Aim of the study. The objective of the present study was to determine the dose dependent effects of lisinopril, a ACE inhibitor on cardiovascular complications in streptozotocin induced diabetic rats.Materials and methods. Two days old neonatal pups (7-10 g) were used and they were made diabetic by intra-peritoneally (i.p.) injection of 90 mg/kg STZ in citrate buffer solution. Lisinopril was given orally at two different doses of 0.5 mg/kg/day and 3 mg/kg/day, p.o for 8 weeks. After 8 weeks treatment biochemical parameters from blood serum and hemodynamic parameters were analyzed.Results. The significant differences of glucose, insulin, cholesterol, triglyceride, creatinine kinase (CK-MB), lactate dehydrogenase (LDH), CRP level, left ventricular collagen content, cardiac hypertrophy index, left ventricular hypertrophy index in 3 mg/kg/day Lisinopril treated group compared to diabetic group were found. It showed a significant decrease in blood pressure compared to diabetic group.Conclusion. Lisinopril has beneficial effects on diabetes and its associated cardiovascular complications.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.